TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01458600
Drug: L-thyroxin
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
Study: NCT01458600
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
Study: NCT01458600
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
Study: NCT01399450
Drug: paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: paliperidone augmenting on ongoing medication
Study: NCT00236652
Drug: levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03653364
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
Study: NCT01052974
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo.
Study: NCT01409837
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis.
Study: NCT02941549
Drug: Epeleuton
Normalized name: Epeleuton
DrugBank: Epeleuton (DB18100)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02994407
Drug: turoctocog alfa pegol
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months.
Study: NCT01214759
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir 200mg/emtricitabine 300mg once a day
Study: NCT01214759
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400mg twice a day
Study: NCT00724126
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03646266
Drug: Rocuronium Bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration with rocuronium bromide until tidal volume 6ml/kg PBW
Study: NCT01540500
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.66 mg dose on Day 1 and Day 8
Study: NCT01540500
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg Dose on Days 2-8
Study: NCT01685268
Drug: abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg PO daily.
Study: NCT01685268
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO twice daily.
Study: NCT00705406
Drug: Peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg peramivir administered as bilateral 2-mL intramuscular injection
Study: NCT01079806
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
Study: NCT01184885
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
Study: NCT01824225
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00918333
Drug: panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00918333
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04463394
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin administered intravenously
Study: NCT00797056
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF 5 mcg/kg/day SQ daily for 10 days
Study: NCT00797056
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 75 mg/day for 14 days
Study: NCT00797056
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg/day daily for 14 days
Study: NCT01386372
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
Study: NCT00776139
Drug: Cetirizine Hydrochloride 10 mg tablet
Normalized name: cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet
Study: NCT00273052
Drug: metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04056754
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
Study: NCT04056754
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects administered 5mg prednisone twice daily in 28-day cycle.
Study: NCT01263132
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
Study: NCT01375699
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO, by mouth
Study: NCT04022421
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the drug will be taken by one group of the patients daily at a dose of 400mg
Study: NCT01333449
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
Study: NCT04053270
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 16mg subcutaneous implant
Study: NCT02191891
Drug: BI 836845
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
Study: NCT02191891
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
Study: NCT00300404
Drug: pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00300404
Drug: folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03120182
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
Study: NCT01951599
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
Study: NCT02809378
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultra-short acting opioid anesthetics
Study: NCT02291510
Drug: Met DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin delayed-release tablets
Study: NCT02291510
Drug: Met IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin immediate-release tablets
Study: NCT01624038
Drug: Hydroxyurea ,Epiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.
Study: NCT01624038
Drug: hydroxyurea, blood transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
Study: NCT04124003
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT02013817
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 4 weeks, 3 cycles
Study: NCT02955459
Drug: VNRX-5133
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02955459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02297568
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02378129
Drug: Glass Ionomer cement Vidrion R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidrion R (SS White, Gloucester, UK)
Study: NCT02207257
Drug: PER977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversal of edoxaban-induced anticoagulation
Study: NCT02207257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversal of edoxaban-induced anticoagulation
Study: NCT02294734
Drug: GSK2269557
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
Study: NCT02294734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via DISKUS 'device'
Study: NCT02747511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110461
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT04151277
Drug: FOLFOX-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
Study: NCT02929212
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects given acetaminophen to measure gastric emptying
Study: NCT04316364
Drug: SHR-1316、Chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
Study: NCT01670175
Drug: Sirolimus, Cyclophosphamide, Topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
Study: NCT04316364
Drug: Placebo、Chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
Study: NCT03031119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered once or twice daily, with food, in Part A.
Study: NCT03339973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in pre-filled syringe
Study: NCT00490620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BID for 6 months
Study: NCT02145598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
Study: NCT00480870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1p / day for 1 month and 2 / day for 5 months on
Study: NCT00599638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04474314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of once daily Placebo
Study: NCT00453180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo arm will receive placebo pill for duration of study.
Study: NCT00804843
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
Study: NCT00804843
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
Study: NCT00462748
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
Study: NCT00462748
Drug: Comparator: rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
Study: NCT01257607
Drug: MIM-D3 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 Days, BID
Study: NCT01257607
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 Days, BID
Study: NCT01093066
Drug: optimal TURB
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TURB will always try to be optically complete.
Study: NCT01262664
Drug: Prohibitin-TP01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
Study: NCT00945932
Drug: GW870086X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product
Study: NCT00945932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT00556413
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00556413
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01010152
Drug: Codeine Sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg Tablet
Study: NCT01344720
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die.
Study: NCT03201159
Drug: VLX103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg tablets
Study: NCT01424228
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
Study: NCT01270256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered intranasally via NasoNeb nebulizer once daily
Study: NCT00493961
Drug: gonadotropin releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
Study: NCT01742689
Drug: Placebo intranasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline spray identical to desmopressin, administered as 4 sprays
Study: NCT01742689
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository 100 milligram single dose
Study: NCT01867138
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02231385
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time.
Study: NCT02964585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily for 16 weeks
Study: NCT03369717
Drug: Amoxi Clavulanate
Normalized name: Amoxi Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics
Study: NCT03161574
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT01440881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infuses at 0.01MCG/KG/min for 48 hours
Study: NCT00327990
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04397328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention
Study: NCT00300352
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00145587
Drug: Systemic chemotherapy and antibodies
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis.
Study: NCT02264080
Drug: WAL2014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no